Novigenix Collaborates with BioLizard to Develop AI-Based Diagnostic Algorithm for Detecting Colon Cancer

 Novigenix Collaborates with BioLizard to Develop AI-Based Diagnostic Algorithm for Detecting Colon Cancer

Novigenix Collaborates with BioLizard to Develop AI Based Diagnostic Algorithm for Detecting Colon Cancer

Shots:

  • BioLizard to develop an AI-based bioinformatics algorithm supporting the transition of its Immuno-Transcriptomic RT-PCR based product, Colox onto Novigenix’s LITOseek platform for early colon cancer detection as well as with other products under development
  • The collaboration involves BioLizard expertise in bioinformatics, machine learning, AI and data mining to co-develop the clinical diagnostic algorithm for Novigenix’s LITOseek platform
  • Novigenix’s LITOseek platform is a blood Immuno-Transcriptomic sequence platform, analyzing the gene expression modifications induced by the host as the response to triggers like onset of the cancer

Click here to­ read full press release/ article | Ref: Businesswire | Image: Novigenix

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post